City Therapeutics Inc CTY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
City Therapeutics to Present at Upcoming November Investor Conferences
-
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
City Therapeutics Announces Pricing of Upsized Initial Public Offering
Trading Information
- Previous Close Price
- $20.88
- Day Range
- $18.77–21.12
- 52-Week Range
- $18.77–23.88
- Bid/Ask
- $18.36 / $19.11
- Shares Outstanding
- 50.33M
- Market Cap
- $960.84M
- Volume/Avg
- 275,529 / 354,561
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 52.59
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.citytx.com
Valuation
|
Metric
|
CTY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 52.59 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CTY
|
|---|---|
Quick Ratio | 2.70 |
Current Ratio | 2.71 |
Interest Coverage | −28.42 |
Quick Ratio
CTY
Profitability
|
Metric
|
CTY
|
|---|---|
Return on Assets (Normalized) | −43.20% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CTY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Rxg^%vW | LOCK|T^zc | $140B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<^dYYr^ | LOCK|l!#! | $99B | |||
| Moderna Inc
MRNA
| LOCK|$Cc&Vcm | LOCK|!L | $88B | |||
| argenx SE ADR
ARGX
| LOCK|ZLC#kxx | LOCK|>@ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|yd?Ydh | LOCK|H! | $43B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&jq?$%x | LOCK|Xtf$z | $30B | |||
| Incyte Corp
INCY
| LOCK|x&&&ln | LOCK|lq | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|@#z%!fK | LOCK|g#y | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#^<Cw<v | LOCK|<X&c | $21B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|VyqShq | LOCK|&# | $15B |
United States